Evidence map›Paper›PMID 32997500›Full record

ArticleBiochemistry2020

Protease Inhibition Mechanism of Camelid-like Synthetic Human Antibodies.

Dong Hyun Nam, Ki Baek Lee, Evan Kruchowy, Henry Pham, Xin Ge

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Achieving protease substrate-specific inhibition by mAb dual functional selections.Protein science : a publication of the Protein Society · 2026
    Article
  3. Generation of Protease Inhibitory Antibodies by Functional In Vivo Selection.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  4. Substrate derived sequences act as subsite-blocking motifs in protease inhibitory antibodies.Protein science : a publication of the Protein Society · 2023
    Article
  5. Outsmarting Pathogens with Antibody Engineering.Annual review of chemical and biomolecular engineering · 2023
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Dong Hyun NamDepartment of Chemical and Environmental Engineering, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.
Ki Baek LeeDepartment of Chemical and Environmental Engineering, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.
Evan KruchowyDepartment of Chemical and Environmental Engineering, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.
Henry PhamDepartment of Chemical and Environmental Engineering, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.
Xin GeDepartment of Chemical and Environmental Engineering, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.ORCID 0000-0001-7491-7805
University of California, Riverside · US

Funding

Structure-based design of camel-like human selective mAbs against MMPs in diseaseR01GM115672 · NIGMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI GE, XIN · 2016 to 2020
$1.5M
NIGMS NIH HHS R01 GM115672
6 · The paper itself

Abstract

Macromolecular protease inhibitors and camelid single-domain antibodies achieve their enzymic inhibition functions often through protruded structures that directly interact with catalytic centers of targeted proteases. Inspired by this phenomenon, we constructed synthetic human antibody libraries encoding long CDR-H3s, from which highly selective monoclonal antibodies (mAbs) that inhibit multiple proteases were discovered. To elucidate their molecular mechanisms, we performed in-depth biochemical characterizations on a panel of matrix metalloproteinase (MMP)-14 inhibitory mAbs. Assays included affinity and potency measurements, enzymatic kinetics, a competitive enzyme-linked immunosorbent assay, proteolytic stability, and epitope mapping followed by quantitative analysis of binding energy changes. The results collectively indicated that these mAbs of convex paratopes were competitive inhibitors recognizing the vicinity of the active cleft, with their significant epitopes scattered across the north and south rims of the cleft. Remarkably, identified epitopes were the surface loops that were highly diverse among MMPs and predominately located at the prime side of the proteolytic site, shedding light on the mechanisms of target selectivity and proteolytic resistance. Substrate sequence profiling and paratope mutagenesis further suggested that mAb 3A2 bound to the active-site cleft in a canonical (substrate-like) manner, by direct interactions between

Indexed as

AnimalsAntibodies, MonoclonalCamelids, New WorldCatalytic DomainHumansImmunoglobulin Fab FragmentsMatrix Metalloproteinase 14Matrix Metalloproteinase InhibitorsModels, MolecularProteolysisAntibodies, MonoclonalImmunoglobulin Fab FragmentsMatrix Metalloproteinase 14Matrix Metalloproteinase InhibitorsMMP14 protein, human

Identifiers

PMID32997500
PMCPMC7572768
OpenAlexW3090648414

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.